Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Preston Bratcher

TitleAffiliate - NJH
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Pohl K, Nichols DP, Taylor-Cousar JL, Saavedra MT, Strand MJ, Nick JA, Bratcher PE. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS One. 2018; 13(12):e0209026. PMID: 30540818.
      View in: PubMed
    2. Bratcher PE, Malcolm KC. Neutrophils and Bacterial Coinfection: Aiding and Abetting. Am J Respir Cell Mol Biol. 2018 Dec; 59(6):668-669. PMID: 30130423.
      View in: PubMed
    3. Bratcher PE, Hunt KC, Pickard K, Taylor-Cousar JL. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. J Cyst Fibros. 2018 Oct 19. PMID: 30348612.
      View in: PubMed
    4. Xu X, Abdalla T, Bratcher PE, Jackson PL, Sabbatini G, Wells JM, Lou XY, Quinn R, Blalock JE, Clancy JP, Gaggar A. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J. 2017 04; 49(4). PMID: 28381428.
      View in: PubMed
    5. Matsye P, Zheng L, Si Y, Kim S, Luo W, Crossman DK, Bratcher PE, King PH. HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. Glia. 2017 06; 65(6):945-963. PMID: 28300326.
      View in: PubMed
    6. Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, Taylor-Cousar JL, Nick JA. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017 May; 16(3):358-366. PMID: 28025037.
      View in: PubMed
    7. Szul T, Bratcher PE, Fraser KB, Kong M, Tirouvanziam R, Ingersoll S, Sztul E, Rangarajan S, Blalock JE, Xu X, Gaggar A. Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via Exosomes. Am J Respir Cell Mol Biol. 2016 Mar; 54(3):359-69. PMID: 26222144.
      View in: PubMed
    8. Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. J Cyst Fibros. 2016 Jan; 15(1):67-73. PMID: 25769931.
      View in: PubMed
    9. Hahn CS, Scott DW, Xu X, Roda MA, Payne GA, Wells JM, Viera L, Winstead CJ, Bratcher P, Sparidans RW, Redegeld FA, Jackson PL, Folkerts G, Blalock JE, Patel RP, Gaggar A. The matrikine N-a-PGP couples extracellular matrix fragmentation to endothelial permeability. Sci Adv. 2015; 1(3). PMID: 26229981.
      View in: PubMed
    10. Bratcher PE, Gaggar A. Factors influencing the measurement of plasma/serum surfactant protein D levels by ELISA. PLoS One. 2014; 9(11):e111466. PMID: 25365324; PMCID: PMC4218753.
    11. Bratcher PE, Gaggar A. Characterization and prevention of the adsorption of surfactant protein D to polypropylene. PLoS One. 2013; 8(9):e73467. PMID: 24039953; PMCID: PMC3770593.
    12. Bratcher PE, Weathington NM, Nick HJ, Jackson PL, Snelgrove RJ, Gaggar A. MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS One. 2012; 7(7):e41881. PMID: 22860023; PMCID: PMC3408449.
    13. Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, Hartl D. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J. 2011 Sep; 38(3):721-7. PMID: 21233269; PMCID: PMC4036453.
    14. Bratcher PE, Park IH, Oliver MB, Hortal M, Camilli R, Hollingshead SK, Camou T, Nahm MH. Evolution of the capsular gene locus of Streptococcus pneumoniae serogroup 6. Microbiology. 2011 Jan; 157(Pt 1):189-98. PMID: 20929956; PMCID: PMC3068628.
    15. Bratcher PE, Nahm MH. Cross-reactivity of current serogroup 6 factor sera from Statens Serum Institut with the recently described pneumococcal serotype 6d. J Clin Microbiol. 2010 Aug; 48(8):3044-5. PMID: 20573866; PMCID: PMC2916608.
    16. Bratcher PE, Kim KH, Kang JH, Hong JY, Nahm MH. Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology. 2010 Feb; 156(Pt 2):555-60. PMID: 19942663; PMCID: PMC2890086.
    17. Rotman E, Bratcher P, Kuzminov A. Reduced lipopolysaccharide phosphorylation in Escherichia coli lowers the elevated ori/ter ratio in seqA mutants. Mol Microbiol. 2009 Jun; 72(5):1273-92. PMID: 19432803; PMCID: PMC2691451.
    18. Bratcher PE, Park IH, Hollingshead SK, Nahm MH. Production of a unique pneumococcal capsule serotype belonging to serogroup 6. Microbiology. 2009 Feb; 155(Pt 2):576-83. PMID: 19202106; PMCID: PMC3706093.
    Bratcher's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)